Sarepta has given StrideBio, a company with expertise in adeno-associated viruses and capsids, a license to research, develop and manufacture up to eight gene therapies. "With our partnership with StrideBio, Sarepta continues to build on its leadership position in gene therapies to treat rare diseases," said Doug Ingram, CEO. Yourway provides services for cell and gene therapy companies, and has the regulatory expertise needed to support these therapies globally.